Medicare Parts B and D have played an important role in providing seniors with access to the lifesaving treatments they need and have been successful in delivering value to both the health care...
Read More

One of the most common misconceptions about the administration’s proposed Part B International Pricing Index (IPI) Model is that it would improve competition in Medicare. However, mounting...
Read More

One of the most important and successful parts of Medicare Part D is the six protected classes policy which covers patients whose conditions – such as HIV, cancer, and epilepsy, among others – are...
Read More

Since the Department of Health and Human Services (HHS) released the Part B International Pricing Index (IPI) model late last year, there have been a number of inaccurate claims floating around...
Read More

Patients should share in the $166B in rebates and discounts biopharmaceutical companies pay to insurance companies, the government, pharmacy benefit managers and other entities in the supply chain...
Read More

Misaligned incentives in Medicare Part D are increasing costs for seniors with diabetes. While insurers negotiate larger and larger rebates with biopharmaceutical companies each year, seniors...
Read More

At the end of 2018, the Centers for Medicare & Medicaid Services (CMS) introduced a dangerous proposed rule that would weaken the Medicare Part D six protected classes policy. The six protected...
Read More

For over 10 years, one of the cornerstones of the Medicare Part D program has been to ensure the sickest and most vulnerable patients have access to the clinically critical medicines they rely on....
Read More

Today, we are launching the “Prescription for Medicare” campaign which focuses on ensuring that changes made to Medicare are the right prescription for seniors. There’s a lot of talk in Washington...
Read More